Biohaven ltd
BHVN 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
BHVN 近期報酬表現
0.59%
Biohaven ltd
-0.88%
同產業平均
-0.58%
S&P500
與 BHVN 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
SLNO | Soleno therapeutics inc | 3 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
SPRC | Scisparc ltd | - | 2 分 | 2 分 | - | 1 分 | |
CNTX | Context therapeutics inc | - | 5 分 | 2 分 | 1 分 | 1 分 | |
FEMY | Femasys inc | - | 3 分 | 2 分 | 1 分 | 1 分 | |
TKNO | Alpha teknova inc | - | 2 分 | 2 分 | 1 分 | 1 分 |
- SLNO Soleno therapeutics inc價值 3 分趨勢 3 分波段 2 分籌碼 3 分股利 1 分查看更多
BHVN 公司資訊
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and neuropathic pain; Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates (ADCs) for cancer. The Troriluzole is a new chemical entity (NCE) and tripeptide prodrug of the active metabolite, riluzole.